CA
NZ
UK
AU
IND
US
This marks a significant financial improvement for the company, which previously faced challenges maintaining its market position. Against a sector background where shares of comparable firms like RNAZ fell by 2.1%, VivoSim's compliance aligns with an uptick in confidence among investors, especially after the …
West Pharmaceutical Services Inc. (NYSE: WST) reported second-quarter 2026 revenues of $872.3 million, representing a year-over-year increase of 13.8%. This growth was driven by a 12.7% increase in organic sales. The adjusted-diluted earnings per share (EPS) rose to $2.37, marking a substantial 28.8% increase.
Whitehawk Therapeutics, Inc. (NASDAQ: WHWK) announced an $87.5 million equity financing on August 6, 2026, which is equivalent to around 42% of its market capitalization of $207 million. This infusion of capital positions the company to continue its Phase 1 clinical trials for its …
Net product revenue surged 34% to more than $91 million, primarily driven by strong demand for its Recorlev treatment. This performance aligns well with the consensus estimate for earnings per share (EPS), which came in at $0.00. Positive investment sentiment surrounding Xeris is underscored …
The company achieved a total revenue of $632.6 million, a year-over-year increase of 21.4%. The impressive performance underscores Privia's growth trajectory in the healthcare sector, despite a broader market response. Nonetheless, shares fell 11.2% to $21.28 in recent trading, raising questions about investor sentiment …
REGENXBIO Inc. reported earnings that topped expectations, claiming a net income of $22.7 million, or $0.43 per share, for the quarter ended June 30, 2026. This figure is markedly above the $0.06 consensus estimate, showcasing the company’s operational effectiveness at a time when shares …
Roivant Sciences Ltd. reported a substantial net loss of $290.6 million for the quarter ended June 30, 2026. This figure starkly contrasts with the consensus estimate, highlighting a concerning EPS of $-0.58 for the quarter, worse than the expected $-0.35. Such financial results may …
The figures highlight a continuing trend of losses, despite a market appetite for innovative treatments in the biotech sector. Without any recorded revenue for both the current and previous quarters, concerns about the company's financial health and growth potential could weigh heavily on its …
Scholar Rock Holding Corp (NASDAQ: SRRK) announced the launch of an at-the-market (ATM) offering, aiming to sell up to $200 million in common stock. This approach allows the company to capitalize on favorable market conditions while boosting its liquidity position. The decision comes at …
This loss is greater than the previous year's $18.1 million, as the biopharmaceutical firm intensifies its efforts on several promising trials aimed at cystic fibrosis treatment. The company recorded earnings per share of $-0.60, which missed the consensus estimate of $-0.52. Such performance highlights …
Please wait processing your request...